These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

326 related items for PubMed ID: 17910628

  • 1. The histone deacetylase inhibitor, PXD101, potentiates bortezomib-induced anti-multiple myeloma effect by induction of oxidative stress and DNA damage.
    Feng R, Oton A, Mapara MY, Anderson G, Belani C, Lentzsch S.
    Br J Haematol; 2007 Nov; 139(3):385-97. PubMed ID: 17910628
    [Abstract] [Full Text] [Related]

  • 2. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.
    Pei XY, Dai Y, Grant S.
    Clin Cancer Res; 2004 Jun 01; 10(11):3839-52. PubMed ID: 15173093
    [Abstract] [Full Text] [Related]

  • 3. Bortezomib-induced sensitization of malignant human glioma cells to vorinostat-induced apoptosis depends on reactive oxygen species production, mitochondrial dysfunction, Noxa upregulation, Mcl-1 cleavage, and DNA damage.
    Premkumar DR, Jane EP, Agostino NR, DiDomenico JD, Pollack IF.
    Mol Carcinog; 2013 Feb 01; 52(2):118-33. PubMed ID: 22086447
    [Abstract] [Full Text] [Related]

  • 4. Nuclear factor-kappaB p65 small interfering RNA or proteasome inhibitor bortezomib sensitizes head and neck squamous cell carcinomas to classic histone deacetylase inhibitors and novel histone deacetylase inhibitor PXD101.
    Duan J, Friedman J, Nottingham L, Chen Z, Ara G, Van Waes C.
    Mol Cancer Ther; 2007 Jan 01; 6(1):37-50. PubMed ID: 17237265
    [Abstract] [Full Text] [Related]

  • 5. KD5170, a novel mercaptoketone-based histone deacetylase inhibitor, exerts antimyeloma effects by DNA damage and mitochondrial signaling.
    Feng R, Ma H, Hassig CA, Payne JE, Smith ND, Mapara MY, Hager JH, Lentzsch S.
    Mol Cancer Ther; 2008 Jun 01; 7(6):1494-505. PubMed ID: 18566220
    [Abstract] [Full Text] [Related]

  • 6. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma.
    Heider U, von Metzler I, Kaiser M, Rosche M, Sterz J, Rötzer S, Rademacher J, Jakob C, Fleissner C, Kuckelkorn U, Kloetzel PM, Sezer O.
    Eur J Haematol; 2008 Feb 01; 80(2):133-42. PubMed ID: 18005386
    [Abstract] [Full Text] [Related]

  • 7. The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571.
    Yu C, Rahmani M, Conrad D, Subler M, Dent P, Grant S.
    Blood; 2003 Nov 15; 102(10):3765-74. PubMed ID: 12893773
    [Abstract] [Full Text] [Related]

  • 8. Bortezomib interacts synergistically with belinostat in human acute myeloid leukaemia and acute lymphoblastic leukaemia cells in association with perturbations in NF-κB and Bim.
    Dai Y, Chen S, Wang L, Pei XY, Kramer LB, Dent P, Grant S.
    Br J Haematol; 2011 Apr 15; 153(2):222-35. PubMed ID: 21375523
    [Abstract] [Full Text] [Related]

  • 9. A Bim-targeting strategy overcomes adaptive bortezomib resistance in myeloma through a novel link between autophagy and apoptosis.
    Chen S, Zhang Y, Zhou L, Leng Y, Lin H, Kmieciak M, Pei XY, Jones R, Orlowski RZ, Dai Y, Grant S.
    Blood; 2014 Oct 23; 124(17):2687-97. PubMed ID: 25208888
    [Abstract] [Full Text] [Related]

  • 10. The pan-histone deacetylase inhibitor CR2408 disrupts cell cycle progression, diminishes proliferation and causes apoptosis in multiple myeloma cells.
    Baumann P, Junghanns C, Mandl-Weber S, Strobl S, Oduncu F, Schmidmaier R.
    Br J Haematol; 2012 Mar 23; 156(5):633-42. PubMed ID: 22211565
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Inhibition of p38alpha MAPK enhances proteasome inhibitor-induced apoptosis of myeloma cells by modulating Hsp27, Bcl-X(L), Mcl-1 and p53 levels in vitro and inhibits tumor growth in vivo.
    Navas TA, Nguyen AN, Hideshima T, Reddy M, Ma JY, Haghnazari E, Henson M, Stebbins EG, Kerr I, O'Young G, Kapoun AM, Chakravarty S, Mavunkel B, Perumattam J, Luedtke G, Dugar S, Medicherla S, Protter AA, Schreiner GF, Anderson KC, Higgins LS.
    Leukemia; 2006 Jun 23; 20(6):1017-27. PubMed ID: 16617327
    [Abstract] [Full Text] [Related]

  • 13. Noxa up-regulation and Mcl-1 cleavage are associated to apoptosis induction by bortezomib in multiple myeloma.
    Gomez-Bougie P, Wuillème-Toumi S, Ménoret E, Trichet V, Robillard N, Philippe M, Bataille R, Amiot M.
    Cancer Res; 2007 Jun 01; 67(11):5418-24. PubMed ID: 17545623
    [Abstract] [Full Text] [Related]

  • 14. Synergistic induction of apoptosis in multiple myeloma cells by bortezomib and hypoxia-activated prodrug TH-302, in vivo and in vitro.
    Hu J, Van Valckenborgh E, Xu D, Menu E, De Raeve H, De Bruyne E, Xu S, Van Camp B, Handisides D, Hart CP, Vanderkerken K.
    Mol Cancer Ther; 2013 Sep 01; 12(9):1763-73. PubMed ID: 23832122
    [Abstract] [Full Text] [Related]

  • 15. Bortezomib and SAHA synergistically induce ROS-driven caspase-dependent apoptosis of nasopharyngeal carcinoma and block replication of Epstein-Barr virus.
    Hui KF, Lam BH, Ho DN, Tsao SW, Chiang AK.
    Mol Cancer Ther; 2013 May 01; 12(5):747-58. PubMed ID: 23475956
    [Abstract] [Full Text] [Related]

  • 16. Vorinostat enhances the antimyeloma effects of melphalan and bortezomib.
    Campbell RA, Sanchez E, Steinberg J, Shalitin D, Li ZW, Chen H, Berenson JR.
    Eur J Haematol; 2010 Mar 01; 84(3):201-11. PubMed ID: 19929977
    [Abstract] [Full Text] [Related]

  • 17. MDM2 antagonist nutlin plus proteasome inhibitor velcade combination displays a synergistic anti-myeloma activity.
    Saha MN, Jiang H, Jayakar J, Reece D, Branch DR, Chang H.
    Cancer Biol Ther; 2010 Jun 01; 9(11):936-44. PubMed ID: 20418664
    [Abstract] [Full Text] [Related]

  • 18. [Study on histone deacetylase inhibitor LBH589 induces apoptosis of multiple myeloma cells and its reversal of drug resistance mechanism].
    Zhang L, Ma YP, Jia G.
    Zhonghua Xue Ye Xue Za Zhi; 2012 Nov 01; 33(11):926-31. PubMed ID: 23363750
    [Abstract] [Full Text] [Related]

  • 19. The novel inhibitor of histone deacetylase resminostat (RAS2410) inhibits proliferation and induces apoptosis in multiple myeloma (MM) cells.
    Mandl-Weber S, Meinel FG, Jankowsky R, Oduncu F, Schmidmaier R, Baumann P.
    Br J Haematol; 2010 May 01; 149(4):518-28. PubMed ID: 20201941
    [Abstract] [Full Text] [Related]

  • 20. Antiproliferative and proapoptotic effects of proteasome inhibitors and their combination with histone deacetylase inhibitors on leukemia cells.
    Fuchs O, Provaznikova D, Marinov I, Kuzelova K, Spicka I.
    Cardiovasc Hematol Disord Drug Targets; 2009 Mar 01; 9(1):62-77. PubMed ID: 19275578
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.